Source comparison
CJC-1295 with DAC vs Without DAC: Pharmacokinetic Differences
The two primary variants of CJC-1295 differ fundamentally in their pharmacokinetics and duration of action, making them suitable for different research applications. CJC-1295 with DAC (Drug Affinity Complex): The DAC is a carrier moiety composed of collagen-bi
This comparison does not assign a generated winner or score.
- The two primary variants of CJC-1295 differ fundamentally in their pharmacokinetics and duration of action, making them suitable for different research applications.
- CJC-1295 with DAC (Drug Affinity Complex): The DAC is a carrier moiety composed of collagen-binding domain sequences that extend the half-life of CJC-1295 dramatically. In research settings, CJC-1295 with DAC exhibits a circulating half-life of approximately 7-8 days, compared to the much shorter half-life of unmodified CJC-1295. This extended half-life is achieved because the DAC facilitates binding of CJC-1295 to serum albumin and other blood proteins, reducing renal clearance and extending the duration of the compound in circulation.
- The practical research advantage of CJC-1295 with DAC is that it can be administered less frequently — typically once every 5-7 days — whilst maintaining relatively stable circulating levels of the compound and consistent GH stimulation. This makes it valuable for long-term research studies where frequent dosing would be impractical or where investigation of sustained GH elevation is the research objective.
- CJC-1295 without DAC: The non-DAC variant of CJC-1295 has a significantly shorter half-life, approximately 30-60 minutes, similar to the half-life of modified GRH-releasing hormones. This shorter duration means that CJC-1295 without DAC produces acute, brief pulses of GH secretion following administration. Research using this variant typically involves more frequent dosing — often multiple times daily — to achieve desired GH elevation profiles.
- The research advantage of CJC-1295 without DAC is that it allows investigators to study the acute effects of GHRH stimulation and to produce distinct GH pulses that more closely mimic the natural pulsatile pattern of GH secretion. Additionally, the shorter duration of action allows for more precise temporal control over GH stimulation in experimental protocols.
- From a research design perspective, the choice between CJC-1295 with DAC and without DAC depends on whether the study objective is to investigate sustained GH elevation (favouring the DAC variant) or acute pulsatile GH secretion (favouring the non-DAC variant).